Agenus Inc. arrives at its May 18 results announcement with short sellers quietly adding pressure through a rough month for the stock.
The most notable tension entering this week is the divergence between a steadily rising short position and options traders who show almost no interest in downside protection — a split that makes the earnings read harder to call.
Short interest has climbed throughout May and is now running at roughly 13.5% of the free float, up 12.5% over the past month and 4.2% over the past week alone. That is a meaningful and growing bet against a $149 million market-cap biotech trading at $3.58. At the same time, cost to borrow has jumped sharply — rising 57% over the past week to 1.14% APR, the highest level in the 30-day window. Borrow availability is currently around 108% of short interest, which means the lending pool is modestly tighter than neutral but still workable; there are just over one share available for every share already borrowed. The ORTEX short score of 70.5 places AGEN in the bottom decile of the universe on the short score percentile rank — a signal that the overall short-side setup is more charged than most small-cap biotech peers.
Options traders tell a strikingly different story. The put/call ratio is running at 0.15, barely above its 20-day average of 0.14 and well within normal range. The 52-week high for the PCR is 0.63, meaning today's reading is near the floor of what this ticker has seen. Put buying is essentially absent ahead of a known earnings catalyst — a posture that sits at odds with the building short position in the equity borrow market.
The Street offers limited fresh guidance. Analyst coverage is thin, and the most recent changes on record — from HC Wainwright and Baird — date back to mid-2025, well beyond the six-month threshold for treating them as current. The mean price target of $15.50 cited in the dataset reflects those stale views and is not consistent with the stock's current $3.58 price, so that figure should be treated with caution. What is known is that the fundamental debate centres on whether botensilimab and balstilimab can generate meaningful compassionate-use revenue and build enough real-world evidence to support a regulatory path — against the risk of safety signals or efficacy shortfalls in a crowded immuno-oncology field.
The earnings history adds important context. The last quarterly print on May 11 sent the stock down nearly 10% on the day. The March 31 release moved it 4.9% higher on day one, then 25% over five days — the kind of volatility that explains why short sellers are willing to pay rising borrow costs to maintain positions. Among correlated peers, ANNX dropped 8.4% on the week and EDIT fell 15.8%, suggesting the broader small-cap biotech tape has been under sustained pressure that has not spared AGEN's own 6.3% weekly decline.
The May 18 announcement is the next inflection point. Whether the widening gap between rising short interest and subdued options hedging resolves through a squeeze, a continuation, or simply a muted post-print tape is the setup worth monitoring.
See the live data behind this article on ORTEX.
Open AGEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
